Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Dana-Farber Cancer Institute

Status and phase: Completed; Phase 2

Conditions: Mesothelioma

Treatments: Drug: Bevacizumab; Drug: Erlotinib

Study type: Interventional

Funder types: Other

Identifiers

NCT00137826

03-369

Details and patient eligibility

About

The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.

Full description

Each cycle of study treatment lasts 21 days. The patient will take erlotinib by mouth once daily. On day 1 of every cycle, the patient will receive bevacizumab intravenously over a 30-90 minute time period.

CT scan(s), MRI(s) and/or x-ray(s) of the cancer site will be performed every 6 weeks (2 cycles) to assess the extent of the response to treatment.

Bloodwork will be performed before the first dose of erlotinib and bevacizumab at Cycle 1, Cycle 2, Cycle 3, and at the end of treatment.

At the completion of the treatment a physical exam, vital signs, blood tests, urine tests and standard radiologic testing will be performed.

The duration of study depends upon how the patients' mesothelioma responds to treatment as well as how well the patient tolerates the medication.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mesothelioma that has been previously treated with at least one chemotherapy regimen
• 18 years of age or older
• Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities
• Four or more weeks since last major surgery
• Four or more weeks since last radiation therapy
• Three or more weeks since last chemotherapy
• Life expectancy of 12 weeks or more
• Blood tests that show kidneys, liver and bone marrow to be working adequately
• Able to comply with study and/or follow-up procedures

Exclusion criteria

• Prior exposure to Tarceva (OSI-774, erlotinib), trastuzumab, ZD1839 or C225
• Receiving anticoagulation medication other than low dose Coumadin
• Clinically significant heart disease such as uncontrolled hypertension, previous heart attack within past 12 months, uneven heartbeat, etc.
• History of central nervous system disease such as seizures not controlled with standard medical therapy, brain metastases or history of stroke
• Major surgery within 28 days of screening
• Daily treatment with aspirin or anti-inflammatory medications
• Pregnant or lactating (pertaining to women only)
• Serious or nonhealing wound, ulcer or bone fracture
• Difficulty swallowing
• A disease or disorder that interferes with ability to digest and absorb food
• History of coughing up more than 1/4 teaspoon of blood
• A medical condition that could make it unsafe for patient to participate in this study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)